ARS Pharmaceuticals logo

ARS Pharmaceuticals

SPRY | NASDAQ
Chart Builder DCF Calculator
$3.59
-$0.30 (-7.71%)
At close: Nov 16, 2026, 4:00 PM ET
$3.59
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-7.71%

Rating

Updated: Nov 16, 2026
44.4
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #408/1021 (Top 40%)

Key Statistics

Market Data

Market Cap $360.9M
1D Range
3.59 3.99
52W Range
2.65 13.06

Valuation (TTM)

PE -1.78
PB -30.19
EV/EBITDA -1.16

Valuation (NTM)

Forward PE N/A
Forward PEG -0.36
Price Target $15.00
Loading financial charts...

Profile

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individu...

Sector Healthcare
Industry Biotechnology
Employees 195
IPO Date Dec 4, 2020
Fiscal Year January - December

Latest News

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

5 months ago · benzinga.com

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins
ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January

5 months ago · investors.com

ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January
ARS Pharmaceuticals Provides Commercial and Financial Updates

5 months ago · globenewswire.com

ARS Pharmaceuticals Provides Commercial and Financial Updates

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.36
Miss -18.03%
REV
$37.71M
Miss -10.20%
Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$15.00
Upside
+317.83%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.